Free Trial
NASDAQ:RVPH

Reviva Pharmaceuticals Q3 2023 Earnings Report

Reviva Pharmaceuticals logo
$0.78 +0.07 (+10.35%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$0.79 +0.00 (+0.46%)
As of 04/17/2025 06:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals EPS Results

Actual EPS
-$0.44
Consensus EPS
-$0.35
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Reviva Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Reviva Pharmaceuticals Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 14, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Reviva Pharmaceuticals' next earnings date is estimated for Monday, April 21, 2025, based on past reporting schedules.

Reviva Pharmaceuticals Earnings Headlines

RVPH: M&A Deals Highlight Brilaroxazine Value
Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
Unusually active option classes on open February 12th
See More Reviva Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals (NASDAQ:RVPH), a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

View Reviva Pharmaceuticals Profile

More Earnings Resources from MarketBeat